Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacillus subtilis RBD oral vaccine
- Development stage
- Unknown
- Lead developer
- DreamTec
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Bacillus subtilis RBD oral vaccine is an experimental recombinant bacterial vector vaccine developed by DreamTec Limited for the prevention of COVID-19. The vaccine consists of *Bacillus subtilis* spores that have been genetically engineered to express and display the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein on their surface. Designed for oral administration, the spores are highly resilient, allowing them to pass through the stomach's acidic environment and reach the small intestine. There, they interact with the gut-associated lymphoid tissue (GALT) to stimulate both mucosal (secretory IgA) and systemic (IgG) immune responses. This platform is intended to provide a cold-chain independent, needle-free vaccination option, particularly as a booster for individuals with waning immunity.
- Other names
- Oral Bacillus subtilis spore COVID-19 vaccine (RBD)DreamTec COVID-19 oral vaccine
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on Bacillus subtilis RBD oral vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bacillus subtilis RBD oral vaccine.